Arcturus Therapeutics Holdings Inc. cotiza a 12.61 USD y tiene una capitalización bursátil de $358M. En los últimos 12 meses ha facturado $29M con un margen de flujo de caja libre del -90.8%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNA…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.84 | $-0.95 | $-1.03 |
| Estimado | $-0.68 | $-1.03 | $-1.01 | $-0.76 |
| Sorpresa | — | +18.4% | +5.9% | -35.5% |
| Métrica | ARCT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -93.0% | -38.6% | -54.3% |
| Net Margin | -80.2% | -33.6% | -46.6% |
| FCF Margin | -90.8% | -13.9% | -77.0% |
| ROE | -30.7% | -40.4% | +9.7% |
| ROA | -24.3% | -32.0% | +7.7% |
| Current Ratio | 6.64 | 2.84 | +3.80 |
| Debt / Equity | — | 0.28 | — |